Sort
8,912 grants matching “sars cov 2”
Data Management for Molecule Simulation : A Throughput-Oriented Approach
$287,698Yicheng Tu · University Of South Florida · R01 · FY2021 · GM
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
$287,587Monica Kraft · University Of Arizona · U19 · FY2024 · AI
Alphavirus Vectored Vaccines for the SARS Coronavirus
$287,577Robert E. Johnston · Univ Of North Carolina Chapel Hill · P01 · FY2008 · AI
Collaborative Research: Ultrasensitive Nucleic Acid Sensing Tools Based on Cas Assays and Solid-State Nanopores
$287,403Minjun Kim · Southern Methodist University · · FY2021 · ENG
Chimeric ACE2 peptide ligand for diagnostic assays of SARS-CoV-2
$287,390Alexander Wlodawer · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Serum Antibody Profiling with a Carbohydrate Microarray
$287,385Jeffrey Gildersleeve · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Biology of ACE2 activity in the airway epithelium
$287,168Paul B McCray · University Of Iowa · P01 · FY2015 · AI
Data Management for Molecule Simulation : A Throughput-Oriented Approach
$287,142Yicheng Tu · University Of South Florida · R01 · FY2024 · GM
Core-- Animal Models
$286,575Mark T Heise · Univ Of North Carolina Chapel Hill · P01 · FY2006 · AI
Determining factors of transmission and evolution of SARS-CoV-2 in populations at risk
$286,534Elodie Ghedin · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Acid-mediated processes in nucleic acids and proteins
$286,294Charles L Brooks · University Of Michigan At Ann Arbor · R01 · FY2014 · GM
Identifying and Testing Post-Overdose Outreach Adaptations to Enhance Survivor Engagement During the COVID-19 Pandemic
$286,019Alexander Yale Walley · Boston Medical Center · R21 · FY2021 · DA
Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
$285,928Daniel Kulp · Wistar Institute · P01 · FY2025 · AI
Biology of ACE2 activity in the airway epithelium
$285,870Paul B McCray · University Of Iowa · P01 · FY2013 · AI
Structure of the SARS-CoV-2 Nucleocapsid: building block to viral capsid
$285,857Erica Ollmann Saphire · La Jolla Institute For Immunology · R21 · FY2023 · AI
Very rapid, low cost multiplexed test for SARS, Influenza A and Influenza B Resubmission
$285,597Gregory W Faris · Numentus Technologies Inc. · R43 · FY2022 · AI
Pre-clinical Vaccine and Antibody Development for Coronavirus Disease 2019 (COVID-19)
$285,362Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIC · FY2022 · AI
Pre-clinical Vaccine and Antibody Development for Coronavirus Disease 2019 (COVID-19)
$285,362Wing Pui Kong · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI
SBIR, Phase I (R43): Ultrasensitive Lateral Flow Assays Enabled by Fluorescent Nanodiamond Labels
$285,269Olga A Shenderova · Adamas Nanotechnologies, Inc. · R43 · FY2022 · CK
Acid-mediated processes in nucleic acids and proteins
$285,226Charles L Brooks · University Of Michigan At Ann Arbor · R01 · FY2015 · GM
Data Management for Molecule Simulation : A Throughput-Oriented Approach
$285,048Yicheng Tu · University Of South Florida · R01 · FY2023 · GM
Human Immune Monitoring Core
$285,027Holden T. Maecker · Stanford University · U19 · FY2023 · AI
Molecular Characterization of the SARS-CoV-2 Helicase and High-Throughput Screening to Identify Small Molecule SARS-CoV-2 Helicase Inhibitors as Anti-Viral Medicines
$285,006Robert Brosh · National Institute On Aging · ZIA · FY2023 · AG
DMS/NIGMS 2: Integrated Analysis of Fusion Protein Conformational Changes for Virus Entry
$284,953Jin Liu · Washington State University · R01 · FY2025 · GM
DMS/NIGMS 2: Integrated Analysis of Fusion Protein Conformational Changes for Virus Entry
$284,953Jin Liu · Washington State University · R01 · FY2024 · GM